Natco Pharma has launched a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Plus in India.
The product is a generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg tablets used for the treatment of patients with chronic Hepatitis C virus infection, the company said in a filing to the BSE.
Natco Pharma has launched the drug at a maximum retail price of Rs 17,500 for a bottle of 28 tablets. Shares of Natco Pharma were trading down by 2.01 per cent at Rs 787.35 on the BSE.